BUZZ-Aurinia Pharmaceuticals Inc: Rises on positive study results
** Canadian drug developer's U.S.-listed shares up 14 pct at $3.01 after market
** Company says investigational drug Voclosporin achieved primary and all pre-specified secondary endpoints in its phase IIb AURA-LV study for lupus nephritis
** Lupus nephritis is a serious condition that involves inflammation of the kidney
** Up to Thursday's close, stock had risen about 7 pct this year
© Thomson Reuters 2017 All rights reserved.